Blocking the angiopoietin-2-dependent integrin β-1 signaling axis abrogates small cell lung cancer invasion and metastasis

Affiliations

• 1 Friedrich-Alexander-Universität Erlangen-Nürnberg, Faculty of Medicine, Department of Experimental Medicine 1, Erlangen, Germany.
• 2 Mildred Scheel School of Oncology and.
• 3 Department I of Internal Medicine, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany.
• 4 Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
• 5 Department of Translational Genomics and.
• 6 Institute of Virology, Laboratory of Experimental Immunology, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany.
• 7 Department of Medical Oncology, Dana-Faber Cancer Institute, Boston, Massachusetts, USA.
• 8 Cancer Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
• 9 Institute for Pathology, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany.
• 10 Else Kröner Forschungskolleg Clonal Evolution in Cancer, University Hospital Cologne, Cologne, Germany.
• 11 German Hodgkin Study Group, Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
• 12 Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Faculty of Medicine at the University Hospital Cologne, Cologne, Germany.
• 13 University Hospital Regensburg, Department of Internal Medicine III, Hematology and Medical Oncology, Regensburg, Germany.
• 14 Department of Pharmacology, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
• 15 Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, German Cancer Consortium (DKTK), Essen, Germany.